featured
Ramucirumab Plus Paclitaxel as Switch Maintenance vs Continuation of First-Line Oxaliplatin-Based Chemotherapy in Patients With Advanced HER2-Negative Gastric or Gastro-Oesophageal Junction Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol 2024 Dec 01;25(12)1539-1550, G Randon, S Lonardi, M Fassan, F Palermo, S Tamberi, E Giommoni, C Ceccon, S Di Donato, L Fornaro, O Brunetti, F De Vita, A Bittoni, C Chini, A Spallanzani, F Nappo, V Bethaz, A Strippoli, T Latiano, GG Cardellino, F Giuliani, F Morano, M Niger, A Raimondi, M Prisciandaro, CC Pircher, C Sciortino, S Marchesi, SK Garattini, G Airò, R Miceli, M Di Bartolomeo, F PietrantonioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.